A new study from Scripps Research suggests that some proof-of-concept HIV vaccines in early human trials generate antibodies that actively hinder protection by degrading the vaccine's payload. ...
Some proof-of-concept HIV vaccines in early human trials generate antibodies that actively hinder protection by degrading the vaccine's payload, suggests a new study from Scripps Research. ...